痤疮哪个医院较好阜阳阜阳祛除痤疮的医院,阜阳治疗足癣的好医生,阜阳治疗白斑的好方法,阜阳地区治疗皮肤病最好,阜阳看干癣的价钱,阜阳中医皮肤医院看去痘印,阜阳一般扁平疣费用

LOS ANGELES, July 19 (Xinhua) -- Obesity prevalence was 30 percent or higher in 12 states of the United States last year, compared to nine states in 2009, the Centers for Disease Control and Prevention (CDC) said on Tuesday.In 2000, no states in the country had obesity rates that high, and now obesity is a problem in all 50 states, the agency said in a report based on telephone interviews with 400,000 people.Obesity rates vary by region, led by the South at 29.4 percent, followed by the Midwest at 28.7 percent, the Northeast at 24.9 percent, and the West at 24.1 percent, the report said.Mississippi had the nation's highest obesity prevalence at 34 percent, and Colorado the lowest at 21 percent, according to the report.Alabama, Arkansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Oklahoma, South Carolina, Tennessee, Texas, and West Virginia all had obesity rates of 30 percent or higher in 2010, said the report.No state met the federal Healthy People 2010 goal of a 15 percent obesity rate. In fact, no state had a rate lower than 20 percent, the CDC said.Obesity rates have kept rising despite a steady drumbeat of warnings that obesity causes serious health problems and increases the risk of premature death, CDC officials said.An adult is considered obese if he or she has a body mass index (BMI) of 30 or greater.

WASHINGTON, June 21 (Xinhua) -- A new study from Harvard School of Public Health (HSPH) and University of California, San Francisco, researchers suggests that men with prostate cancer who smoke increase their risk of prostate cancer recurrence and of dying from the disease. The study will be published Wednesday in the Journal of the American Medical Association."In our study, we found similar results for both prostate cancer recurrence and prostate cancer mortality," said Stacey Kenfield, lead author and a research associate in the HSPH Department of Epidemiology. "These data taken together provide further support that smoking may increase risk of prostate cancer progression."Kenfield and her colleagues conducted a prospective observational study of 5,366 men diagnosed with prostate cancer between 1986 and 2006 in the Health Professionals Follow-Up Study. The researchers documented 1,630 deaths, 524 (32 percent) due to prostate cancer, 416 (26 percent) due to cardiovascular disease, and 878 prostate cancer recurrences.The researchers found that men with prostate cancer who were current smokers had a 61 percent increased risk of dying from prostate cancer, and a 61 percent higher risk of recurrence compared with men who never smoked. Smoking was associated with a more aggressive disease at diagnosis, defined as a higher clinical stage or Gleason grade (a measure of prostate cancer severity). However, among men with non-metastatic disease at diagnosis, current smokers had an 80 percent increased risk of dying from prostate cancer.Compared with current smokers, men with prostate cancer who had quit smoking for 10 or more years, or who had quit for less than 10 years but smoked less than 20 pack-years before diagnosis, had prostate cancer mortality risk similar to men who had never smoked. Men who had quit smoking for less than 10 years and had smoked 20 or more pack-years had risks similar to current smokers."These data are exciting because there are few known ways for a man to reduce his risk of dying from prostate cancer," said senior author Edward Giovannucci, professor of nutrition and epidemiology at HSPH. "For smokers, quitting can impact their risk of dying from prostate cancer. This is another reason to not smoke."Prostate cancer is the most frequently diagnosed form of cancer diagnosed in the United States and the second leading cause of cancer death among U.S. men, affecting one in six men during their lifetime. More than two million men in the U.S. and 16 million men worldwide are prostate cancer survivors.

LOS ANGELES, July 5 (Xinhua) -- NASA's Juno spacecraft is 30 days away before its first launch window opens, the Jet Propulsion Laboratory (JPL) announced on Tuesday."One month from today, our first launch window opens at 11:34 a. m. EDT (8:34 a.m. PDT) and lasts 69 minutes," said Jan Chodas, Juno project manager from NASA's JPL in Pasadena, Los Angeles."Our primary launch period is 22 days long, and so if weather or other issues come up on Aug. 5, we have 21 more days to get Juno flying. Once we get Juno into space, it's a five-year cruise to Jupiter.""The launch window is the length of time allotted every day for an attempt to launch the spacecraft," said Chodas. "The launch period is the period of time in days when everything is in the right place to get your mission off to the right start."For a mission like Juno, getting everything in the right place includes considering the size of the rocket and spacecraft, where our home planet -- and in particular Juno's launch pad -- is pointed at any moment, and its location in space relative to other celestial objects like Juno's final target, Jupiter.Juno is scheduled to launch aboard a United Launch Alliance Atlas V rocket from pad 41-C at the Cape Canaveral Air Force Station, Florida.The solar-powered spacecraft will orbit Jupiter's poles 33 times to find out more about the gas giant's origins, structure, atmosphere and magnetosphere and investigate the existence of a solid planetary core.JPL manages the Juno mission for the principal investigator, Scott Bolton, of Southwest Research Institute in San Antonio.The Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska. Lockheed Martin Space Systems, Denver, built the spacecraft.

LOS ANGELES, June 5 (Xinhua) -- A latest study has found no evidence that screening for ovarian cancer may reduce the risk of dying from the disease, it was reported on Sunday.Screening, however, does increase the likelihood of unnecessary invasive procedures, according to researchers at the University of Utah.The researchers presented their findings at an on-going meeting of the American Society of Clinical Oncology in Chicago, The Los Angeles Times said.Researchers studied 78,216 women, ages 55 to 74, who participated in the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Half of the women received the usual care from their OB-gyns, and half received a CA 125 screening every year for six years and an ultrasound every year for four years. They were then followed for a maximum of 12 years.The researchers observed 212 ovarian cancers in the screened group and 176 in the normal care group. There were 118 ovarian cancer deaths in the screened group and 100 in the normal care group. The differences were not statistically significant. Overall, there were 2,924 deaths from all causes in the screened group and 2,914 in the normal care group.But the researchers also observed that 3,285 women had false- positive diagnoses from the screening. Among those, 1,080 underwent surgery that included an oophorectomy (surgical removal of one or both ovaries). Fifteen percent of those who had surgery developed major complications as a result. Overall, 1,771 women in the screened group (7.7 percent) had an oophorectomy, compared with 1,304 in the normal care group (5.8 percent)."We conclude that annual screening for ovarian cancer ... does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms," the researchers said in the study.New data presented at the meeting also showed that the widely used cancer drug Avastin can improve treatment of ovarian cancer, The Times said.About 21,880 American women are diagnosed with ovarian cancer each year and about 13,850 die from it, according to the American Cancer Society. Because it produces few symptoms, the disease is typically not diagnosed until it has become advanced and spread throughout the body. As a result, five-year survival is only about 30 percent, and the disease is one of the five most deadly cancers among women. Being able to detect the cancer at an earlier stage when it might be more curable could thus, theoretically, improve the survival rate.The tests most commonly used to detect ovarian cancer include a transvaginal ultrasound to look for tumor masses and a blood test that screens for increased levels of a tumor marker called CA 125.

SAN FRANCISCO, July 12 (Xinhua) -- U.S. videogame giant Electronic Arts Inc. (EA) on Tuesday said it has agreed to buy PopCap Games, a leading provider of casual games for digital platforms, in a deal to accelerate its digital transformation.EA said it will pay about 650 million U.S. dollars in cash and 100 million dollars in shares of EA common stock to acquire privately-held PopCap, the maker of blockbuster games including " Plants vs. Zombies," "Bejeweled" and "Zuma".In addition, PopCap's owners are entitled to receive as much as 550 million dollars in earn-outs if certain earnings targets are met through December 2013, according to EA, which is headquartered in Redwood City in the U.S. state of California.Logos of PopCap Games and Electronic Arts Inc."EA and PopCap are a compelling combination," John Riccitiello, EA's chief executive officer, said in a statement."PopCap's great studio talent and powerful IP add to EA's momentum and accelerate our drive towards a 1-billion-dollar digital business," he noted.PopCap is one of the largest providers of casual videogames for mobile phones, tablets, PCs and social network sites, with more than 150 million games installed and played worldwide on platforms such as Facebook, RenRen, Google, iPhone, iPad and Android.EA said the purchase of PopCap is expected to close in August this year, subject to customary closing conditions including regulatory approvals.